Overdose : מינון יתר

11 OVERDOSAGE
In the event of suspected overdose, immediately interrupt Kerendia treatment. The most likely manifestation of overdose is hyperkalemia. If hyperkalemia develops, standard treatment should be initiated.
Finerenone is unlikely to be efficiently removed by hemodialysis given its fraction bound to plasma proteins of about 90%.

12 DESCRIPTION
Kerendia contains finerenone, a nonsteroidal mineralocorticoid receptor antagonist. Finerenone’s chemical name is (4S)- 4-(4-cyano-2- methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide. The molecular formula is C21H22N4O3 and the molecular weight is 378.43 g/mol. The structural formula is: 


Finerenone is a white to yellow crystalline powder. It is practically insoluble in water; and sparingly soluble in 0.1 M HCl, ethanol, and acetone.
Each Kerendia tablet contains 10 mg or 20 mg of finerenone. The inactive ingredients of Kerendia are cellulose microcrystalline, lactose monohydrate, croscarmellose sodium, hypromellose, magnesium stearate and sodium lauryl sulfate. The film coating contains hypromellose, titanium dioxide and talc, in addition to ferric oxide red (10 mg strength tablets) or ferric oxide yellow (20 mg strength tablets).